Table 2.
Interim results on vaccine efficacy
| Total cases | Vaccine group | Placebo group | Vaccine efficacy (95% CI) | p value | ||
|---|---|---|---|---|---|---|
| First COVID-19 occurrence from 21 days after dose 1 (day of dose 2)* | ||||||
| Overall | 78 | 16/14 964 (0·1%) | 62/4902 (1·3%) | 91·6% (85·6–95·2) | <0·0001 | |
| Age group (years) | ||||||
| 18–30 | 5 | 1/1596 (0·1%) | 4/521 (0·8%) | 91·9% (51·2–99·3) | 0·0146 | |
| 31–40 | 17 | 4/3848 (0·1%) | 13/1259 (1·0%) | 90·0% (71·1–96·5) | <0·0001 | |
| 41–50 | 19 | 4/4399 (0·1%) | 15/1443 (1·0%) | 91·3% (73·7–96·9) | <0·0001 | |
| 51–60 | 27 | 5/3510 (0·1%) | 22/1146 (1·9%) | 92·7% (81·1–97·0) | <0·0001 | |
| >60 | 10 | 2/1611 (0·1%) | 8/533 (1·5%) | 91·8% (67·1–98·3) | 0·0004 | |
| Sex | ||||||
| Female | 32 | 9/5821 (0·2%) | 23/1887 (1·2%) | 87·5% (73·4–94·2) | <0·0001 | |
| Male | 46 | 7/9143 (0·1%) | 39/3015 (1·3%) | 94·2% (87·2–97·4) | <0·0001 | |
| Moderate or severe cases | 20 | 0/14 964 | 20/4902 (0·4%) | 100% (94·4–100·0) | <0·0001 | |
| First COVID-19 occurrence after dose 1† | ||||||
| Any time after dose 1 | 175 | 79/16 427 (0·5%) | 96/5435 (1·8%) | 73·1% (63·7–80·1) | <0·0001 | |
| From 14 days after dose 1 | 109 | 30/14 999 (0·2%) | 79/4950 (1·6%) | 87·6% (81·1–91·8) | <0·0001 | |
| First COVID-19 occurrence after dose 2 (28 days after dose 1)* | ||||||
| All | 60 | 13/14 094 (0·1%) | 47/4601 (1·0%) | 91·1% (83·8–95·1) | <0·0001 | |
Data are n/N (%), unless otherwise stated.
*
Includes those who received both doses.
†
Includes participants who received at least one dose.